--- title: "Evidence: raises antioxidant capacity, lowers MDA" description: "Astaxanthin supplementation improved markers of inflammation and oxidative stress, and enhanced ART outcomes in infertile women with endometriosis." url: "https://magellanlongevity.com/study/s107.md" canonical: "https://magellanlongevity.com/study/s107.html" html: "https://magellanlongevity.com/study/s107.html" type: "study" study_key: "s107" journal: "Front Endocrinol" year: 2023 pmid: "37020589" doi: "10.3389/fendo.2023.1144323" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Evidence: raises antioxidant capacity, lowers MDA [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Evidence: raises antioxidant capacity, lowers MDA **HTML version:** https://magellanlongevity.com/study/s107.html · **In the Magellan app:** https://magellanlongevity.com/#/study/s107 ## Citation | Field | Value | | --- | --- | | Journal | Front Endocrinol | | Year | 2023 | | PMID | [37020589](https://pubmed.ncbi.nlm.nih.gov/37020589/) | | DOI | [10.3389/fendo.2023.1144323](https://doi.org/10.3389/fendo.2023.1144323) | | Study key | s107 | ## Takeaway Astaxanthin supplementation improved markers of inflammation and oxidative stress, and enhanced ART outcomes in infertile women with endometriosis. ## The question What is the effect of Astaxanthin (AST) on pro-inflammatory cytokines, oxidative stress (OS) markers, and early pregnancy outcomes in infertile women with endometriosis undergoing assisted reproductive techniques (ART)? ## Hypothesis The study hypothesized that Astaxanthin (AST) treatment would modulate inflammation and oxidative stress markers, and improve early pregnancy outcomes in infertile women with endometriosis undergoing ART. ## Methods This was a randomized, triple-blind, placebo-controlled clinical trial involving 50 infertile women with stage III/IV endometriosis who were candidates for ART. Participants received 6 mg of AST per day for 12 weeks. Blood serum and follicular fluid (FF) samples were collected before and after treatment to measure pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and OS markers (MDA, SOD, CAT, TAC). ART outcomes were also compared between the groups. ## Results After AST therapy, the treatment group showed increased serum levels of TAC (398.661 vs. 364.746) and SOD (13.458 vs. 9.040), and decreased serum MDA (14.619 vs. 15.939). Significantly lower serum levels of IL-1β (4.515 vs. 6.8760), IL-6 (5.516 vs. 5.0543), and TNF-α (2.520 vs. 2.968) were also observed. Additionally, AST supplementation led to an improved number of oocytes retrieved (14.60 vs. 9.84), mature (MII) oocytes (10.48 vs. 6.72), and high-quality embryos (4.52 vs. 2.72). ## Conclusion AST pretreatment can modulate inflammation and oxidative stress in infertile patients with endometriosis, and improve ART outcomes after 12 weeks of therapy. These results suggest AST could be a potential therapeutic target for this patient population. ## Limitations The abstract does not explicitly state any limitations of the study. ## Verbatim from the abstract > Increased serum levels of total antioxidant capacity and SOD were observed after astaxanthin ## Changes in Oxidative Stress Markers and Oocyte Retrieval After AST Treatment | Measure | Value | | --- | --- | | Serum TAC (After AST) | 398.661 | | Serum TAC (Before AST) | 364.746 | | Serum SOD (After AST) | 13.458 | | Serum SOD (Before AST) | 9.04 | | Serum MDA (After AST) | 14.619 | | Serum MDA (Before AST) | 15.939 | | Oocytes Retrieved (After AST) | 14.6 | | Oocytes Retrieved (Before AST) | 9.84 | *This chart illustrates the changes in key oxidative stress markers (TAC, SOD, MDA) and the number of oocytes retrieved in infertile women with endometriosis after 12 weeks of Astaxanthin treatment compared to before treatment.* ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Astaxanthin Softgels | Moderate evidence | [Astaxanthin Softgels](https://magellanlongevity.com/p/107.md) | ## Reference 1. **Evidence: raises antioxidant capacity, lowers MDA** Front Endocrinol 2023 · [PMID 37020589](https://pubmed.ncbi.nlm.nih.gov/37020589/) · [DOI 10.3389/fendo.2023.1144323](https://doi.org/10.3389/fendo.2023.1144323) > Increased serum levels of total antioxidant capacity and SOD were observed after astaxanthin ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/s107.html#page","url":"https://magellanlongevity.com/study/s107.html","name":"Evidence: raises antioxidant capacity, lowers MDA","description":"Astaxanthin supplementation improved markers of inflammation and oxidative stress, and enhanced ART outcomes in infertile women with endometriosis.","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/s107.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Evidence: raises antioxidant capacity, lowers MDA","item":"https://magellanlongevity.com/study/s107.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/s107.html#study","name":"Evidence: raises antioxidant capacity, lowers MDA","headline":"Evidence: raises antioxidant capacity, lowers MDA","datePublished":"2023","isPartOf":{"@type":"Periodical","name":"Front Endocrinol"},"identifier":"PMID:37020589","url":"https://pubmed.ncbi.nlm.nih.gov/37020589/","sameAs":"https://doi.org/10.3389/fendo.2023.1144323","abstract":"Astaxanthin supplementation improved markers of inflammation and oxidative stress, and enhanced ART outcomes in infertile women with endometriosis."}]} ``` ## Related on Magellan Longevity - [Astaxanthin Softgels](https://magellanlongevity.com/p/107.md) — product graded on this and related evidence - [Effects of Astaxanthin Supplementation on Oxidative Stress](https://magellanlongevity.com/study/d30982442.md) - [Astaxanthin supplementation impact on insulin resistance, lipid profile, blood pressure,…](https://magellanlongevity.com/study/d37874168.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).